التفاصيل البيبلوغرافية
| العنوان: |
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes |
| المؤلفون: |
Filippatos, Gerasimos, Anker, Stefan D., Pitt, Bertram, Rossing, Peter, Joseph, Amer, Kolkhof, Peter, Lambelet, Marc, Lawatscheck, Robert, Bakris, George L., Ruilope, Luis M., Agarwal, Rajiv |
| المصدر: |
JACC: Heart Failure; November 2022, Vol. 10 Issue: 11 p860-870, 11p |
| مستخلص: |
In patients with type 2 diabetes (T2D), risks of cardiovascular mortality and heart failure (HF) increase with decreasing kidney function (estimated glomerular filtration rate [eGFR]) and increasing albuminuria (urine albumin-to-creatinine ratio [UACR]). Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and T2D in FIDELITY (Finerenone in Chronic Kidney Disease and Type 2 Diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial Programme Analysis). |
| قاعدة البيانات: |
Supplemental Index |
Full Text Finder